| Year |
Citation |
Score |
| 2020 |
Witty DR, Alvaro G, Derjean D, Giblin GMP, Gunn K, Large C, Macpherson DT, Morisset V, Owen D, Palmer J, Rugiero F, Tate S, Hinckley CA, Naik H. Discovery of Vixotrigine: A Novel Use-Dependent Sodium Channel Blocker for the Treatment of Trigeminal Neuralgia. Acs Medicinal Chemistry Letters. 11: 1678-1687. PMID 32945812 DOI: 10.1021/Acsmedchemlett.0C00263 |
0.631 |
|
| 2018 |
Zakrzewska JM, Palmer J, Bendtsen L, Di Stefano G, Ettlin DA, Maarbjerg S, Obermann M, Morisset V, Steiner D, Tate S, Cruccu G. Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience. Trials. 19: 704. PMID 30587219 DOI: 10.1186/s13063-018-3045-1 |
0.307 |
|
| 2017 |
Zakrzewska JM, Palmer J, Morisset V, Giblin GM, Obermann M, Ettlin DA, Cruccu G, Bendtsen L, Estacion M, Derjean D, Waxman SG, Layton G, Gunn K, Tate S. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. The Lancet. Neurology. PMID 28216232 DOI: 10.1016/S1474-4422(17)30005-4 |
0.614 |
|
| 2016 |
Tanaka BS, Zhao P, Dib-Hajj FB, Morisset V, Tate S, Waxman SG, Dib-Hajj SD. A gain-of-function mutation in Nav1.6 in a case of trigeminal neuralgia. Molecular Medicine (Cambridge, Mass.). 22. PMID 27496104 DOI: 10.2119/Molmed.2016.00131 |
0.386 |
|
| 2013 |
Zakrzewska JM, Palmer J, Ettlin DA, Obermann M, Giblin GM, Morisset V, Tate S, Gunn K. Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia. Trials. 14: 402. PMID 24267010 DOI: 10.1186/1745-6215-14-402 |
0.365 |
|
| 2006 |
Amaya F, Wang H, Costigan M, Allchorne AJ, Hatcher JP, Egerton J, Stean T, Morisset V, Grose D, Gunthorpe MJ, Chessell IP, Tate S, Green PJ, Woolf CJ. The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 12852-60. PMID 17167076 DOI: 10.1523/JNEUROSCI.4015-06.2006 |
0.385 |
|
| 2006 |
Lappin SC, Randall AD, Gunthorpe MJ, Morisset V. TRPV1 antagonist, SB-366791, inhibits glutamatergic synaptic transmission in rat spinal dorsal horn following peripheral inflammation. European Journal of Pharmacology. 540: 73-81. PMID 16737693 DOI: 10.1016/j.ejphar.2006.04.046 |
0.377 |
|
| 2003 |
Derjean D, Bertrand S, Le Masson G, Landry M, Morisset V, Nagy F. Dynamic balance of metabotropic inputs causes dorsal horn neurons to switch functional states. Nature Neuroscience. 6: 274-81. PMID 12592405 DOI: 10.1038/Nn1016 |
0.568 |
|
| 2001 |
Morisset V, Urban L. Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. Journal of Neurophysiology. 86: 40-8. PMID 11431486 DOI: 10.1152/Jn.2001.86.1.40 |
0.319 |
|
| 2000 |
Morisset V, Nagy F. Plateau potential-dependent windup of the response to primary afferent stimuli in rat dorsal horn neurons. The European Journal of Neuroscience. 12: 3087-95. PMID 10998092 DOI: 10.1046/J.1460-9568.2000.00188.X |
0.609 |
|
| 1999 |
Morisset V, Nagy F. Ionic basis for plateau potentials in deep dorsal horn neurons of the rat spinal cord. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 19: 7309-16. PMID 10460237 DOI: 10.1523/Jneurosci.19-17-07309.1999 |
0.615 |
|
| 1998 |
Morisset V, Nagy F. Nociceptive integration in the rat spinal cord: role of non-linear membrane properties of deep dorsal horn neurons. The European Journal of Neuroscience. 10: 3642-52. PMID 9875343 DOI: 10.1046/J.1460-9568.1998.00370.X |
0.593 |
|
| 1996 |
Morisset V, Nagy F. Modulation of regenerative membrane properties by stimulation of metabotropic glutamate receptors in rat deep dorsal horn neurons. Journal of Neurophysiology. 76: 2794-8. PMID 8899647 |
0.567 |
|
| Show low-probability matches. |